|Budget Amount *help
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|Outline of Final Research Achievements
The optimal conditions for preparation of micro-cardiac tissues (MCT) were determined. Their maturity and the importance of the oxygen supply were confirmed. We established a massive two-dimensional culture method of human iPS cell-derived cardiomyocytes to obtain high-quality cardiomyocytes. MCT were transplanted to hearts of immunodeficient mice. The transplanted MCT were engrafted in large quantities even in the long term after transplantation, and vascular network was confirmed. MCT was transplanted to myocardial infarction models in immunodeficient rats, as well. A large number of transplanted MCT were engrafted, and their cardiac function significantly improved even in the long term after transplantation. The engrafted MCT expressed connexin 43 and did not induce any lethal arrhythmia. From these results, it has become clear that MCT based on high-quality human cardiomyocytes has vascular network, and safely and efficiently improves cardiac function in heart failure.